2 completed, 1 unknown. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow lestaurtinib: new trials by email Literature Review of lestaurtinib trials Research Report on lestaurtinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CEP-701 (Lestaurtinib) in Myelofibrosis CEP-701 (Lestaurtinib) - Myelofibrosis, Essential Thrombocythemia | Phase 1 / Phase 2 | Unknown | Ronald Hoffman | 60 | 2008-04-01 | 2014-11-26 |
| Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia cytarabine, idarubicin, lestaurtinib - Leukemia | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 14 | 2007-06-01 | 2017-03-15 |
| N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma lestaurtinib - Neuroblastoma | Phase 1 | Completed | New Approaches to Neuroblastoma Therapy Consortium | 47 | 2003-08-01 | 2023-04-10 |
Congenital Abnormalities (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Neuroblastoma (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1)
Children's Oncology Group (1) · New Approaches to Neuroblastoma Therapy Consortium (1) · Ronald Hoffman (1)
United States (3) · Canada (1)
Donald Small, MD, PhD (1) · Garrett M. Brodeur, MD (1) · John M. Maris, MD (1) · Patrick A. Brown, MD (1) · Ronald Hoffman, MD (1)
P01CA081403 (1), P01CA108671 (1)